Edith Mathiowitz “The distribution [of orally delivered protein-based medicines] in the body can be somehow controlled with the type of polymer that you use.” Credit: Mike Cohea/Brown University
In a new study, a “bioadhesive” coating developed at Brown University significantly improved the intestinal absorption into the bloodstream of nanoparticles that someday could carry protein drugs such as insulin.
Such a step is necessary for drugs taken by mouth, rather than injected directly into the blood.
For protein-based drugs such as insulin to be taken orally rather than injected, bioengineers need to find a way to shuttle them safely through the stomach to the small intestine where they can be absorbed and distributed by the bloodstream. Progress has been slow, but in a new study, researchers report an important technological advance: They show that a “bioadhesive” coating significantly increased the intestinal uptake of polymer nanoparticles in rats and that the nanoparticles were delivered to tissues around the body in a way that could potentially be controlled.
“The results of these studies provide strong support for the use of bioadhesive polymers to enhance nano- and microparticle uptake from the small intestine for oral drug delivery,” wrote the researchers in the Journal of Controlled Release, led by corresponding author Edith Mathiowitz, professor of medical science at Brown University.
Mathiowitz, who teaches in Brown’s Department of Molecular Pharmacology, Physiology, and Biotechnology, has been working for more than a decade to develop bioadhesive coatings that can get nanoparticles to stick to the mucosal lining of the intestine so that they will be taken up into its epithelial cells and transferred into the bloodstream. The idea is that protein-based medicines would be carried in the nanoparticles.
In the new study, which appeared online June 21, Mathiowitz put one of her most promising coatings, a chemical called PBMAD, to the test both on the lab bench and in animal models. Mathiowitz and her colleagues have applied for a patent related to the work, which would be assigned to Brown University.
In prior experiments, Mathiowitz and her group have shown not only that PBMAD has bioadhesive properties, but also that it withstands the acidic environment of the stomach and then dissolves in the higher pH of the small intestine.
Adhere, absorb, arrive
The newly published results focused on the question of how many particles, whether coated with PBMAD or not, would be taken up by the intestine and distributed to tissues. For easier tracking throughout the body, Mathiowitz’s team purposely used experimental and control particles made of materials that the body would not break down. Because they were “non-erodible” the particles did not carry any medicine.
The researchers used particles about 500 nanometers in diameter made of two different materials: polystyrene, which adheres pretty well to the intestine’s mucosal lining, and another plastic called PMMA, that does not. They coated some of the PMMA particles in PBMAD, to see if the bioadhesive coating could get PMMA particles to stick more reliably to the intestine and then get absorbed.
The Latest Bing News on:
Oral protein-based drugs
- Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q1 2022 Results - Earnings Call Transcripton May 12, 2022 at 6:32 pm
As you know, seclidemstat is an oral reversible protein inhibitor ... of the widely studied drug avadomide with the potential for increased efficacy and improved safety. Based on published reports ...
- SK bioscience's typhoid vaccine licensed for export by Korean Ministry of Food and Drug Safetyon May 12, 2022 at 6:57 am
The International Vaccine Institute (IVI) and SK bioscience announced today that SK bioscience obtained an export license from the Korean Ministry of Food and Drug Safety for SK's typhoid vaccine ...
- Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administrationon May 11, 2022 at 1:07 pm
Salarius planning for SP-3164 IND Application Submission in 2023HOUSTON, May 11, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company ...
- Study Reveals Potential of New COVID-19 Oral Vaccineon May 10, 2022 at 10:47 pm
New oral COVID-19 vaccine candidate uses an adenovirus as a vector to express the spike protein of SARS-CoV-2 and elicits a robust antibody response in the blood.
- EpicentRx Announces Oral and Poster Presentations at the 2022 American Thoracic Society (ATS) Respiratory Innovation Summiton May 10, 2022 at 3:00 am
EpicentRx, Inc., a privately-held clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer and other inflammatory-driven diseases, ...
- How to Treat Oral Cancer at the Early Stage?on April 26, 2022 at 3:52 pm
The dialing back or even genetically deleting a protein ... drug that helps white blood cells in the immune system kill cancer cells. These findings provide a basis for future clinical studies ...
- Could blocking or deleting a protein help prevent common oral cancers?on April 26, 2022 at 1:14 am
They say their findings make the protein ... clinical studies based on the inhibition of LSD1, either as monotherapy or in combination with other agents to treat oral cancer in humans," he ...
- Could blocking or deleting a protein help prevent common oral cancers?on April 25, 2022 at 2:46 pm
They say their findings make the protein ... clinical studies based on the inhibition of LSD1, either as monotherapy or in combination with other agents to treat oral cancer in humans,” he ...
- Roche breast cancer drug fails in Phase 2 following similar stumble by rival Sanofion April 25, 2022 at 9:28 am
A Roche drug that’s part of a new class of medicines for breast cancer has failed a Phase 2 study, marking the latest stumble in a burgeoning field of oral therapies that degrade a protein key ...
- Could blocking or deleting a protein help prevent common oral cancers?on April 24, 2022 at 5:00 pm
Around one-third of people with oral squamous cell carcinoma don't survive it, but dental researchers have found deleting or inhibiting a protein in ... or used a type of drug called a small ...
The Latest Google Headlines on:
Oral protein-based drugs
The Latest Bing News on:
Bioadhesive
- Implantable device delivers personalized photodynamic therapyon May 10, 2022 at 2:05 am
Personalizing PDT: The small optoelectronic device is designed to individualize light dosing and provide more effective photodynamic therapy. (Courtesy: Justin Baetge/Texas A&M Engineering) ...
- Daré Bioscience (DARE) Scheduled to Post Earnings on Thursdayon May 6, 2022 at 7:34 am
Daré Bioscience (NASDAQ:DARE – Get Rating) will post its quarterly earnings results after the market closes on Thursday, May 12th. Analysts expect Daré Bioscience to post earnings of ($0.14) per share ...
- Bioadhesive Market Size 2022 Share, Current Sales Analysis, Upcoming Trends, Opportunities, Development History and Future Forecast to 2025on May 6, 2022 at 1:09 am
Global "Bioadhesive Market" Research Report is an intelligence report with meticulous efforts undertaken to study the ...
- Replens review 2022on April 29, 2022 at 9:30 am
The moisturizer contains a bioadhesive that helps the product attach to dry vaginal cells to deliver its moisturizing effects over a longer period of time. According to the Replens website ...
- How mussels maintain adhesion underwateron April 12, 2022 at 10:03 am
MAP is gaining attention as a biomedical material used as a bioadhesive or a drug delivery system as it is nature-derived and harmless to the body. However, there was a limitation in that Dopa ...
- Prof. Dr. Andreas Henselon August 17, 2020 at 10:07 pm
Highly acidic, pectin-like polysaccharides show exhibit high bioadhesive activity against epithelial human tissue, especially against GUT tissue (buccal and colonic mucosa). These bioadhesive polymer ...
- Purdue Lifestyles Briefson August 2, 2018 at 3:32 am
"Using a bioadhesive material to deliver drugs through the skin is not new, but this material is, and the way it is made is an innovation," says Nicholas Peppas, the Showalter Distinguished Professor ...